# Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

> **NCT07132528** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Liaoning Cancer Hospital & Institute** · enrollment: 1000 (estimated)

## Conditions studied

- Gastric / Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** SOX plus PD-1 inhibitor
- **DRUG:** SOX Chemotherapy

## Key facts

- **NCT ID:** NCT07132528
- **Lead sponsor:** Liaoning Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-31
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-09-30
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132528, "Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07132528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*